PubRank

Soldano Ferrone

Author PubWeight™ 207.36‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009 3.30
2 Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002 3.00
3 Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009 2.25
4 Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010 2.12
5 PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol 2009 2.12
6 Immunotherapy of cancer in 2012. CA Cancer J Clin 2012 2.12
7 For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res 2012 2.09
8 NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 2009 2.08
9 Lost in Translation: Obstacles to Translational Medicine. J Transl Med 2004 2.03
10 HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008 1.77
11 Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 2004 1.68
12 Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 2005 1.68
13 Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 2003 1.67
14 HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 2006 1.65
15 Monoclonal antibodies for cancer immunotherapy. Lancet 2009 1.64
16 Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013 1.63
17 Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004 1.56
18 Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003 1.55
19 Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clin Cancer Res 2011 1.54
20 Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006 1.49
21 Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 2014 1.49
22 Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006 1.48
23 Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol 2005 1.48
24 Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 2007 1.47
25 Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 2006 1.45
26 Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 2010 1.45
27 Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res 2006 1.43
28 Polyclonality of BRAF mutations in acquired melanocytic nevi. J Natl Cancer Inst 2009 1.40
29 HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002 1.39
30 Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 2010 1.37
31 Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003 1.36
32 Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 2013 1.35
33 HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 2005 1.35
34 Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 2007 1.35
35 Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 2005 1.32
36 Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer 2006 1.32
37 Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells 2008 1.28
38 Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 2005 1.27
39 Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 2011 1.26
40 CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst 2010 1.26
41 Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery 2006 1.25
42 A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods 2005 1.25
43 Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res 2005 1.25
44 Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther 2008 1.23
45 Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol 2005 1.23
46 HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 2005 1.22
47 Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 2006 1.19
48 Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 2004 1.18
49 Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res 2007 1.18
50 SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin Cancer Res 2013 1.18
51 HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol 2003 1.17
52 Mechanisms of immune evasion of human neuroblastoma. Cancer Lett 2005 1.17
53 Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer 2010 1.16
54 Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res 2005 1.15
55 Soluble HLA-G: Are they clinically relevant? Semin Cancer Biol 2007 1.15
56 Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 2005 1.13
57 Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res 2011 1.11
58 Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 2008 1.11
59 Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother 2011 1.11
60 Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 2005 1.10
61 Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 2003 1.10
62 Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother 2008 1.10
63 Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 2004 1.10
64 CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res 2011 1.09
65 Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res 2009 1.09
66 The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008 1.09
67 Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res 2008 1.09
68 Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother 2009 1.08
69 mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem 2009 1.07
70 Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Mod Pathol 2011 1.07
71 Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol 2004 1.07
72 Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol Immunother 2008 1.05
73 Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 2005 1.05
74 Melanoma cells inhibit NK cell functions. Cancer Res 2012 1.04
75 HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer 2007 1.04
76 Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res 2011 1.04
77 Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res 2009 1.03
78 Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J Immunol Methods 2003 1.03
79 Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med 2011 1.02
80 A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res 2010 1.02
81 Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 2003 1.01
82 Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res 2010 1.01
83 MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer 2004 1.01
84 Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. J Immunother 2009 1.01
85 Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 2013 1.01
86 Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res 2003 1.00
87 Immunogenicity of human neuroblastoma. Ann N Y Acad Sci 2004 1.00
88 DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res 2005 1.00
89 Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms. Ann N Y Acad Sci 2004 0.99
90 HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002 0.99
91 Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunol Immunother 2008 0.98
92 Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci 2010 0.98
93 The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 2005 0.98
94 Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 2006 0.98
95 Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. Neoplasia 2009 0.98
96 A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecol Oncol 2012 0.97
97 NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant 2010 0.95
98 Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med 2013 0.95
99 PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget 2014 0.94
100 HLA class I defects in malignant lesions: what have we learned? Keio J Med 2003 0.94
101 Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem 2006 0.93
102 Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes? Immunol Invest 2006 0.93
103 Differential contribution of TAP and tapasin to HLA class I antigen expression. Immunology 2008 0.93
104 HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Curr Opin Immunol 2004 0.92
105 Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head Neck 2011 0.92
106 WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol 2007 0.92
107 Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood 2009 0.92
108 CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res 2012 0.92
109 Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. Cancer Immunol Immunother 2008 0.91
110 Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Res 2007 0.91
111 Immunotherapy dispenses with tumor antigens. Nat Biotechnol 2004 0.91
112 Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol Immunother 2009 0.90
113 Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J Immunol 2005 0.90
114 Mechanisms of tumor evasion. Cancer Treat Res 2005 0.90
115 Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res 2011 0.90
116 Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res 2012 0.90
117 Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother 2011 0.89
118 Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human gammadelta T lymphocytes. Cell Immunol 2002 0.89
119 Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study. Am J Pathol 2012 0.89
120 T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res 2013 0.89
121 Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells. Cancer Res 2007 0.88
122 Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer 2007 0.88
123 Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients. Int J Oncol 2011 0.88
124 NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunol Immunother 2007 0.87
125 Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother 2008 0.87
126 Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol 2006 0.87
127 Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med 2012 0.87
128 Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Hum Immunol 2003 0.87
129 Blocking the formation of radiation-induced breast cancer stem cells. Oncotarget 2014 0.87
130 Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol 2005 0.86
131 Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells. J Immunol 2009 0.86
132 Cancer immunotherapy: Progress and challenges in the clinical setting. Eur J Immunol 2011 0.86
133 Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer 2010 0.86
134 Levels of antigen processing machinery components in dendritic cells generated for vaccination of HIV-1+ subjects. AIDS 2007 0.86
135 Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol 2013 0.86
136 HLA-G in melanoma: can the current controversies be solved? Semin Cancer Biol 2003 0.86
137 Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression. Melanoma Res 2003 0.86
138 Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells. J Immunol 2013 0.85
139 Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer 2005 0.85
140 Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer. Cancer Immunol Immunother 2014 0.85
141 Characterization of human afferent lymph dendritic cells from seroma fluids. J Immunol 2013 0.85
142 A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line. J Biol Chem 2003 0.85
143 Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies. Glia 2010 0.85
144 Specificity of mimotope-induced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity. PLoS One 2011 0.84
145 Immunotherapy of malignant diseases. Challenges and strategies. Int Arch Allergy Immunol 2003 0.84
146 Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. Cancer 2003 0.84
147 Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells. Oncol Rep 2010 0.84
148 HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. Breast Dis 2004 0.84
149 LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res 2013 0.84
150 HLA antigen expression in melanocytic lesions: is acquisition of HLA antigen expression a biomarker of atypical (dysplastic) melanocytes? J Am Acad Dermatol 2012 0.83
151 Peptide and dendritic cell vaccines. Clin Cancer Res 2006 0.83
152 T-Cell activation by t(9;22) acute lymphoblastic leukemia-derived dendritic-like cells is associated with increased tapasin expression. Cancer Immunol Immunother 2005 0.83
153 Immunotherapy of melanoma: the good news, the bad ones and what to do next. Semin Cancer Biol 2003 0.83
154 HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol 2011 0.83
155 Expression and genetic analysis of transporter associated with antigen processing in cervical carcinoma. Gynecol Oncol 2007 0.83
156 A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin Cancer Res 2010 0.82
157 Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. Cancer Immunol Immunother 2008 0.82
158 Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. Eur J Immunol 2009 0.82
159 Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma. Vet J 2011 0.82
160 Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother 2012 0.82
161 Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model. J Transl Med 2007 0.82
162 Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res 2004 0.82
163 Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2'-deoxycytidine. Cell Res 2005 0.81
164 Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. J Immunol Methods 2004 0.81
165 Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells. Cancer Immunol Immunother 2008 0.81
166 Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells. Clin Transpl 2013 0.81
167 Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes. Cancer Immunol Immunother 2008 0.81
168 Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J Immunol 2005 0.81
169 Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients. Cancer Immunol Immunother 2011 0.81
170 IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells. PLoS One 2013 0.81
171 A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. Melanoma Res 2008 0.80
172 Structural basis of antigen mimicry in a clinically relevant melanoma antigen system. J Biol Chem 2005 0.80
173 Emerging BRAF inhibitors for melanoma. Expert Opin Emerg Drugs 2013 0.80
174 Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. Cancer Res 2007 0.80
175 Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med 2014 0.80
176 MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma. Transl Oncol 2012 0.79
177 NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. Semin Cancer Biol 2006 0.79
178 IL-27 in human secondary lymphoid organs attracts myeloid dendritic cells and impairs HLA class I-restricted antigen presentation. J Immunol 2014 0.79
179 Functional idiotopes: tumor antigen-directed expression of CD8+ T-cell epitopes nested in unique NH2-terminal VH sequence of antiidiotypic antibodies? Cancer Res 2005 0.79
180 Contribution of dendritic cells' FcgammaRI and FcgammaRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies. Cancer Biol Ther 2007 0.79
181 CD4-dependent potentiation of a high molecular weight-melanoma-associated antigen-specific CTL response elicited in HLA-A2/Kb transgenic mice. J Immunol 2006 0.78
182 Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression. Melanoma Res 2003 0.78
183 T-cell-based immunotherapy of melanoma: what have we learned and how can we improve? Expert Rev Vaccines 2004 0.78
184 Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy? Int J Cancer 2006 0.78
185 Molecular characterization of the HLA-Cw*0409N allele. Hum Immunol 2002 0.77
186 Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Phys Biol 2015 0.77
187 Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2. Cancer Res 2005 0.77
188 IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells. Mol Immunol 2009 0.76
189 Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation. Cytometry A 2014 0.76
190 IGKC and prognosis in breast cancer--response to Schmidt. Clin Cancer Res 2012 0.76
191 Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases. Cancer Chemother Biol Response Modif 2005 0.76
192 Isolation of human tumor-associated cell surface antigen-binding scFvs. Methods Mol Biol 2002 0.75
193 Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma. Methods Mol Biol 2014 0.75
194 Interferon-γ secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells. Leuk Res 2010 0.75
195 Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting. J Neurooncol 2009 0.75
196 Allorecognition of an HLA-A*01 aberrant allele by an HLA identical family member carrying the HLA-A*0101 allele. J Immunol 2006 0.75
197 Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts. Oncol Res 2015 0.75
198 Multidisciplinary approach to patient with malignant melanoma. Anticancer Agents Med Chem 2013 0.75
199 A tribute to Edgardo Carosella on the occasion of the 6th International Conference on HLA-G held in Paris, France, July 9-11, 2012. Hum Immunol 2012 0.75
200 Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy? Clin Cancer Res 2013 0.75